Author: toxlaw

Different behavioral responses can occur without a detected difference in drug concentration at one sampling time. A developmental PCB-exposure experiment found that male rats responded differently to repeated amphetamine injections, while a later concentration check found no significant exposure-group differences.

The result supports investigating altered responsiveness, but the concentration check was not a complete pharmacokinetic study. Nor was reduced locomotor sensitization evidence that PCB exposure was protective or that addiction risk had been measured.

How did developmental exposure occur?

Poon and colleagues administered a polychlorinated-biphenyl mixture to female Long-Evans rats at 0, 3 or 6 mg/kg/day. The mixture was given orally on a food wafer, beginning 28 days before mating and continuing through weaning on postnatal day 21.

Thus, the developmental treatment was maternal PCB exposure spanning preconception, gestation and lactation. The 3- and 6-mg/kg/day figures were maternal PCB doses, not doses of amphetamine or directly measured doses received by each offspring.

One male and one female offspring per litter underwent behavioral testing. Ten littermate pairs completed testing in each of the control and 3-mg/kg/day groups; nine completed testing in the 6-mg/kg/day group. The analysis accounted for sex nested within litter, rather than treating every offspring as an unrelated developmental-exposure unit.

What amphetamine protocol was used?

Testing began at approximately 75 days of age. Animals were food restricted to about 85% of free-feeding weight. Each session included a 30-minute habituation period, an injection, and 60 minutes of activity recording using infrared photobeam interruptions.

After a saline session on day one, rats received d-amphetamine sulfate at 0.5 mg/kg intraperitoneally on days two through six and again on day ten. Days seven through nine involved neither dosing nor testing.

The study defined sensitization as increased locomotor response with repeated administration. A separate sensitization score subtracted the first amphetamine session’s total beam breaks from those on day ten. That is an activity-change score, not a measure of drug liking, compulsive use or human impairment.

What happened in males?

PCB-exposed males showed greater activation after the first amphetamine injection, but that comparison with controls was significant only in the 3-mg/kg/day PCB group.

Control males showed increased activity by the third amphetamine injection. In PCB-exposed males, the corresponding increase was delayed until the final injection after the three-day break. Their sensitization scores were lower than controls at both PCB exposure levels.

The smaller increase must be interpreted alongside the higher initial response. A change score can be smaller partly because its starting value is larger; it does not necessarily mean the animals were uniformly less responsive throughout the experiment.

The authors discussed possible pre-sensitization followed by tolerance, dopamine-store changes and other mechanisms. These were interpretations of the pattern, not direct measurements of dopamine depletion, transporter abundance or receptor function.

Were the female findings the same?

No exposure-related difference in the final sensitization scores was found in females. Control females developed a significant increase later than control males. The 6-mg/kg/day female group showed a similar late increase, whereas the 3-mg/kg/day female group did not meet the within-group significance criterion.

A significant within-group change in one group and a nonsignificant change in another does not by itself establish a difference between those groups. The reported absence of an exposure effect on female sensitization scores remains an important null finding.

What did the drug measurements actually establish?

After behavioral testing, the researchers gave a final 0.5 mg/kg intraperitoneal amphetamine injection and collected whole brain and a blood-derived specimen ten minutes later. Analyses used a randomly selected subset representing five litters per exposure group.

The source uses inconsistent blood-specimen terminology: parts of the methods refer to plasma, while the extraction description and results table label serum. The table’s concentrations were expressed as ng/g for both whole brain and serum. They should not be silently converted to whole-blood ng/mL or treated as a validated plasma–serum equivalence.

No significant PCB-exposure-group effect was detected in either specimen. For example, male control values were 750.9 ± 181.0 ng/g in whole brain and 134.4 ± 30.8 ng/g in the specimen labeled serum, reported as mean ± standard error.

These measurements argue against a large group difference at that specific post-injection time. They do not establish identical absorption, distribution, metabolism or elimination across the entire exposure period. A single time point after a later injection cannot exclude differences earlier, later or during the behavioral sessions.

What should not be inferred?

The study did not measure self-administration, later dependence, cognition or human outcomes. Less sensitization in an activity assay is not evidence that an environmental contaminant reduces addiction risk or toxicity.

The PCB mixture, developmental exposure window, food restriction, species and small litter-based groups all limit translation. The practical lesson is to preserve both the behavioral pattern and the narrow scope of the concentration check, rather than equating a nonsignificant chemical comparison with proven pharmacokinetic identity.

Scientific source

Poon E, Monaikul S, Kostyniak PJ, Chi LH, Schantz SL, Sable HJK. Developmental Exposure to Polychlorinated Biphenyls Reduces Amphetamine Behavioral Sensitization in Long-Evans Rats. Neurotoxicology and Teratology. 2013;38:6–12. doi:10.1016/j.ntt.2013.04.005. Full-text author manuscript. Historical original developmental-exposure rat experiment.

A laboratory measurement returning toward a control value is not the same as demonstrating brain repair. A 2019 study examined whether one amphetamine infusion changed dopamine dynamics after repeated cocaine self-administration in female rats. Several transporter-related measures moved toward control levels, while other measures were unchanged or differed by brain region.

The experiment adds mechanistic evidence. It did not test clinical recovery, later cocaine use, cognitive improvement or treatment safety in people.

What exposure preceded the amphetamine infusion?

Siciliano and colleagues used adult female Sprague-Dawley rats. After acquiring self-administration, animals completed five days with access to 40 intravenous cocaine injections per day at 1.5 mg/kg per injection. Sessions lasted up to six hours.

The protocol constrained total daily intake. What increased across days was the rate of intake and early-session loading, not an unlimited escalation in the number of daily injections.

Approximately 18 hours after the last cocaine session, animals received a single intravenous amphetamine infusion at 0.56 mg/kg or saline. They were sacrificed one hour later for brain-slice experiments. Controls were naive rats maintained under the same light/dark schedule.

This acute post-exposure infusion was different from continuous amphetamine treatment during ongoing cocaine self-administration. Results from those regimens should not be merged into one presumed mechanism.

Which brain regions and sample sizes were studied?

The researchers examined the nucleus accumbens core and dorsolateral caudate-putamen. For nucleus accumbens measurements, figures report 11 controls, nine cocaine-plus-saline animals and eight cocaine-plus-amphetamine animals. The corresponding dorsolateral-region counts were nine, eight and seven.

These are region-specific analytic denominators. Multiple tissue measurements or concentration steps do not create additional independent rats, and the regional counts should not simply be added to claim a larger independent sample.

What did the tissue assay measure?

Fast-scan cyclic voltammetry measured electrically evoked dopamine signals in isolated brain slices. The researchers modeled release and uptake, then applied cocaine cumulatively in the bath at 0.3–30 micromolar to assess its ability to inhibit dopamine uptake.

The analysis estimated maximal uptake rate and cocaine potency at the dopamine transporter. These are model-derived properties under the assay conditions, not counts of dopamine neurons, measurements of a person’s brain function or human blood concentrations.

Neither cocaine self-administration nor amphetamine treatment significantly changed evoked dopamine release in either region. That null finding limits any claim that all dopamine-system functions were impaired and then restored.

Were uptake changes the same in both regions?

No. In the nucleus accumbens core, the authors reported reduced uptake after cocaine plus saline and a value nearer control after amphetamine. However, the overall uptake analysis had p=.08, while a reported post hoc comparison was below .05. That statistical qualification makes the uptake claim less straightforward than a uniformly significant overall result.

In the dorsolateral caudate-putamen, neither cocaine exposure nor amphetamine significantly altered uptake rate. Thus, reduced baseline uptake was not a common finding across both sampled regions.

What happened to cocaine potency?

After cocaine self-administration plus saline, cocaine was less effective at inhibiting uptake in both regions at selected bath concentrations. Amphetamine-treated animals showed greater cocaine-induced inhibition than the cocaine-plus-saline animals.

In the nucleus accumbens core, the amphetamine group’s concentration–response results did not differ significantly from naive controls. Its model-derived inhibitory constant also returned toward the control pattern.

In the dorsolateral region, amphetamine-treated animals exceeded control inhibition at the highest tested cocaine concentration, 30 micromolar. Yet pairwise comparisons of the summary inhibitory constants were not significant despite a significant overall group effect. A single word such as “normalization” would conceal those distinctions.

Did the findings establish the mechanism of amphetamine treatment?

The authors proposed that reversing cocaine-related transporter adaptations might contribute to effects of amphetamine observed in other studies. This experiment did not measure post-infusion cocaine taking, craving or sustained behavioral improvement.

A plausible mechanism is therefore different from a demonstrated chain linking the tissue change to reduced drug use. No lasting effect beyond the one-hour post-infusion sampling point was established.

Were male and female effects shown to be equivalent?

No concurrent male comparison group was included. The authors compared the female findings with earlier male studies and noted similarities, while also discussing a difference in dopamine-release results.

Estrous-cycle stage was not monitored, although the discussion identified it as a possible influence. Historical cross-study similarity cannot establish sex equivalence or exclude cycle-dependent effects.

The evidence supports a specific conclusion: one amphetamine exposure altered selected ex vivo transporter measurements after a high-intake cocaine regimen in female rats. It does not demonstrate regeneration, reversal of all neural effects, a human therapeutic dose or absence of impairment.

Scientific source

Siciliano CA, Mauterer MI, Fordahl SC, Jones SR. Modulation of striatal dopamine dynamics by cocaine self-administration and amphetamine treatment in female rats. European Journal of Neuroscience. 2019;50(4):2740–2749. doi:10.1111/ejn.14437. Full-text author manuscript. Historical original rat and ex vivo tissue experiment.

A statistical symptom cluster is not automatically a distinct biological disease. A 2009 analysis of stimulant-treatment data identified three classes among primary amphetamine users. The classes mainly differed in symptom severity, including tolerance and withdrawal, rather than establishing separate mechanisms of illness.

The study is historically situated in DSM-IV diagnostic concepts and discussions preceding DSM-5. Its categories should not be presented as current diagnostic instructions or used to classify an individual from a toxicology result.

Which participants were analyzed?

Wu and colleagues performed a secondary analysis of public-use data from a Clinical Trials Network study conducted at eight community-based outpatient treatment programs. The analysis included 415 adults reporting past-year cocaine or amphetamine use.

There were 287 primary cocaine users, 99 primary amphetamine users and 29 dual users. “Primary” here meant reporting one of these stimulant categories without the other during the preceding 12 months. It did not mean that the participant used no alcohol, cannabis, opioids or other substances.

The source questionnaire combined amphetamines and methamphetamine. The data could not determine what proportion used an amphetamine other than methamphetamine. Consequently, the 99-person group cannot be relabeled as 99 analytically confirmed methamphetamine-only users.

What information defined the classes?

The researchers analyzed seven past-year DSM-IV dependence criteria, including tolerance, withdrawal, impaired control, time spent obtaining or using the substance, giving up activities and continued use despite problems.

Latent class analysis estimated groups with different probabilities of endorsing those symptoms. It did not measure blood concentrations, pharmacokinetics, receptor sensitivity or responses to controlled drug doses.

Self-reported tolerance in a diagnostic interview is therefore different from experimentally demonstrating a smaller response at a fixed concentration. The word refers to related ideas, but the measurements are not interchangeable.

Which amphetamine classes were identified?

A three-class model fit the primary amphetamine group better than the tested four-class alternative. The authors labeled approximately 11% as non-dependence, 31% as intermediate physiological dependence and 58% as physiological dependence.

The intermediate and higher-severity classes had broadly similar symptom profiles but different endorsement probabilities. Their mean numbers of endorsed criteria were 4.3 and 6.7, compared with 0.6 in the non-dependence class.

All members assigned to the highest-severity class and 97% of the intermediate class met the study’s DSM-IV dependence definition. None of the non-dependence class did. These are relationships within this model and selected treatment sample, not prevalence estimates for the general population.

Did the cocaine group have the same structure?

No. A four-class model was selected for the 287 primary cocaine users. It included classes characterized by compulsive use without prominent physiological symptoms, tolerance with compulsive use, a high-symptom physiological-dependence profile, and low or absent dependence symptoms.

In the amphetamine group, reported withdrawal was common—82%, compared with 57% in the cocaine group—and clustered with other symptoms. The authors considered that one reason the model did not separate an additional compulsive-use-only amphetamine class.

This difference does not prove that such a subgroup cannot exist. Class structure depends on sample composition, symptom measurement, sample size and model selection. The smaller amphetamine sample also supported fewer stable distinctions.

What did the sex-related findings show?

Among primary amphetamine users, 71% of women and 44% of men were assigned to the highest-severity class; 20% and 42%, respectively, were assigned to the intermediate class. The reported overall association had p=.022.

These percentages concern classification within a treatment-seeking sample. They do not establish that female sex caused greater dependence severity, that every woman had a more severe disorder, or that biological sex differences explained the association.

The authors discussed possible differences in help-seeking and other factors, but did not directly test a complete causal explanation. Group membership also cannot identify an individual’s clinical needs without assessment.

Why is “national” different from nationally representative?

The programs were geographically diverse, which strengthened the analysis compared with a single-site sample. Recruitment nevertheless occurred among people attending selected treatment programs. It was not a national probability survey of stimulant users.

People outside treatment, people at other types of programs and people with different substance-use patterns may have different symptom distributions. Memory and reporting errors could affect the self-reported criteria. The 29-person dual-use group was too small for a separate latent-class analysis.

The estimated classification error for the selected amphetamine model was .08. That model quantity is not an 8% laboratory drug-test error rate, nor proof that every assigned class was known with certainty.

What remains useful today?

The historical study demonstrates that a broad stimulant label can conceal differences in symptoms, co-use and treatment context. It also illustrates the need to distinguish a statistical grouping from a biological mechanism and a historical research definition from current diagnostic practice.

No concentration cutoff, impairment threshold or individual prognosis follows from these classes. The appropriate use of the evidence is to preserve heterogeneity and ask which symptoms and exposures were actually assessed.

Scientific source

Wu LT, Blazer DG, Patkar AA, Stitzer ML, Wakim PG, Brooner RK. Heterogeneity of Stimulant Dependence: A National Drug Abuse Treatment Clinical Trials Network Study. American Journal on Addictions. 2009;18(3):206–218. doi:10.1080/10550490902787031. Full-text author manuscript. Historical secondary analysis of human treatment-sample data using DSM-IV criteria.

A change observed during a dietary manipulation is not necessarily caused by that diet. An eight-baboon experiment tested whether periodic high-sugar candy consumption would blunt d-amphetamine’s suppression of food intake. The expected amphetamine tolerance did not emerge. Follow-up after candy access stopped was central to understanding why.

The study was a controlled nonhuman-primate feeding experiment, not evidence that sugar treats stimulant effects or that changing a person’s diet predictably alters an amphetamine dose response.

How was food access arranged?

Foltin studied eight experimentally naive adult male baboons, initially weighing 17.5–23.1 kg. Animals earned food through operant-response schedules, with brief morning opportunities and longer pellet-meal sessions. They were not simply offered unrestricted candy alongside an otherwise unchanged free-feeding diet.

After baseline drug testing, candy replaced morning pellets on Mondays, Wednesdays and Fridays. Availability increased over successive weeks until up to 200 pieces could be earned on those mornings. Candy supplied approximately 75% of its energy as sugar; the standard pellets supplied about 19%.

Baboons reduced other pellet intake when candy was available and also ate less on non-candy days. The authors reported near compensation across the week and no accelerated rate of weight gain during candy access. High morning candy intake therefore was not equivalent to an equally large sustained increase in total weekly energy.

When were the drugs tested?

D-amphetamine hydrochloride at 0.06–0.5 mg/kg and dexfenfluramine hydrochloride at 0.12–1.0 mg/kg were administered intramuscularly in a thigh muscle at 8:50 a.m. on Tuesdays and Thursdays. Doses were expressed as salt weights.

Those were days without candy. The question was whether the ongoing history of periodic candy access changed responses to drugs while animals earned pellets, rather than whether simultaneously eating candy immediately reversed a drug effect.

Dose–response functions were obtained before candy access, during the candy-access period, and after six months without candy. Dose order was varied within and across animals, with placebo days included. The overall before–during–after sequence was not randomized.

Which outcomes were measured?

The principal measures were pellets earned during brief morning sessions, pellets earned during afternoon meal sessions, and latency to the first afternoon pellet. Latency included a required food-acquisition period; its minimum was approximately 30 minutes under this schedule.

Because baseline pellet intake changed with candy availability, drug results were analyzed as changes from baseline. Those baseline shifts remain important even after adjustment: the same numerical reduction can have a different meaning when the comparison intake is already lower.

No plasma amphetamine, brain dopamine or serotonin concentration was measured in these animals. Proposed neurotransmitter explanations were hypotheses, not direct chemical findings from this experiment.

Did candy access produce the predicted amphetamine tolerance?

The authors concluded that it did not. Their abstract and discussion described increased sensitivity to some amphetamine feeding effects as the study progressed, rather than the predicted blunting. Crucially, the altered amphetamine response persisted after candy access ended.

That persistence weakened an explanation tied specifically to concurrent candy availability. Repeated intermittent amphetamine testing, elapsed time, experience with the task and other sequential changes remained possible contributors.

The paper also contains an interpretive caution: its detailed results prose describes some afternoon amphetamine changes as “smaller,” while the abstract and discussion describe increased sensitivity. The present commentary does not assign a precise endpoint-specific dietary effect from those inconsistent descriptions. The authors’ broader conclusion—that the predicted candy-related amphetamine tolerance was not established—is the defensible emphasis.

Why was the comparison drug useful?

Dexfenfluramine showed a different pattern. Its dose–response function shifted toward reduced sensitivity during candy access and returned toward the earlier pattern after candy stopped. For example, 0.5 mg/kg reduced brief-session pellet intake by about half before and after candy access but had no reported effect on that measure during candy availability.

The contrast demonstrated that the experiment could detect a change associated with the dietary phase. It did not establish that amphetamine and dexfenfluramine act through completely separate systems or that one can use the latter’s result to infer the former’s mechanism.

The author proposed a relationship between repeated palatable-food intake and serotonin-mediated satiation. That interpretation required further testing, including designs able to separate diet from other phase-related experiences.

What limits a causal conclusion?

All eight animals experienced the phases in the same broad temporal order, and drug-testing order differed between phases. There was no concurrent group maintained on the original diet throughout the entire sequence. Candy availability, task history, repeated drug testing and aging were therefore not fully separated.

The sample consisted only of male baboons under a specific food-earning schedule. The type and amount of high-sugar food were limited by the design. The study did not measure human appetite, clinical weight loss, stimulant safety or functional impairment.

Its strongest methodological contribution is the follow-up comparison: a response that persists after a manipulation ends needs a different interpretation from one that returns toward baseline. Neither pattern alone proves its molecular cause, but preserving that distinction prevents an unsupported claim that sugar neutralizes amphetamine.

Scientific source

Foltin RW. Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons. Physiology & Behavior. 2011;103(5):493–500. doi:10.1016/j.physbeh.2011.04.004. Full-text author manuscript. Historical original nonhuman-primate experiment.

A compound can reduce methamphetamine-related behavior in animals and still fail as a drug-development candidate. GZ-793A illustrates that distinction. A 2012 rat study reported favorable effects on methamphetamine self-administration and conditioned preference. A later mechanistic study identified cardiac ion-channel effects and stated that development would not be pursued.

Reading the later evidence alongside the earlier results prevents a historical “promising treatment” description from becoming an unsupported clinical recommendation.

What was GZ-793A designed to do?

GZ-793A was a lobelane-related experimental compound targeting vesicular monoamine transporter-2, or VMAT2. The research program sought to reduce dopamine availability for methamphetamine-induced release and thereby alter methamphetamine’s reinforcing effects.

The studies concern this particular compound. They do not establish that every VMAT2 inhibitor shares its behavioral effects or cardiac liabilities.

What did the early rat experiments find?

Beckmann and colleagues used adult male Sprague-Dawley rats. Animals self-administered intravenous d-methamphetamine hydrochloride at 0.03 mg/kg per infusion under a fixed-ratio-five schedule. GZ-793A was given subcutaneously 20 minutes before sessions, with doses expressed as salt weights.

Acute GZ-793A doses of 10, 15 and 30 mg/kg reduced methamphetamine infusions. In a separate cocaine group, only 30 mg/kg significantly reduced cocaine infusions. Acute food-maintained responding was not significantly reduced under the tested conditions.

Repeated GZ-793A at 15 mg/kg continued to reduce methamphetamine self-administration across seven daily sessions, with four rats per treatment group. The investigators did not observe tolerance over that interval. In a separate food experiment, six rats per group showed increased pellet earning during later repeated-treatment sessions.

Those control results argue against simple generalized response suppression at the selected dose. They are not a comprehensive assessment of toxicity or long-term safety.

Was the compound itself reinforcing?

When intravenous GZ-793A at 0.01–0.3 mg/kg per infusion replaced methamphetamine, responding did not differ from saline substitution. That experiment used seven rats per group.

In a separate conditioned-place-preference experiment, also with seven animals per group, GZ-793A pretreatment at 15 mg/kg subcutaneously blocked preference associated with 0.5 mg/kg subcutaneous methamphetamine. GZ-793A alone produced neither demonstrated preference nor aversion under that protocol.

Self-administration and place preference are different behavioral assays. Their negative results for GZ-793A suggested low reinforcing potential under those conditions, but did not prove absence of human abuse liability.

What did the later neurochemical study add?

Nickell and colleagues examined isolated rat striatal slices. Methamphetamine at 5 micromolar evoked dopamine release; GZ-793A at selected concentrations reduced that release. The principal methamphetamine-release experiment used tissue from seven rats.

GZ-793A alone did not significantly increase basal dopamine release. It also did not significantly inhibit nicotine-evoked release in the five-rat experiment or electrically stimulated release in experiments involving five to six rats per concentration. These findings supported selectivity among the tested release conditions.

The concentrations were laboratory bath concentrations, not measured human blood levels or doses that can be prescribed. Mechanistic selectivity in brain tissue does not establish selectivity across all organs.

Which cardiac findings changed the development decision?

The later study tested the human ether-a-go-go-related gene channel, commonly called hERG, in engineered human embryonic kidney cells. GZ-793A inhibited radioligand binding with an IC50 of 0.81 ± 0.11 micromolar and inhibited channel current with an IC50 of approximately 0.07 micromolar. The current experiment reported n=3; the binding experiments used several independent cell preparations.

These are two different assays. Binding inhibition and reduced electrical current should not be treated as interchangeable measurements, even though they supported the same concern.

In isolated rabbit cardiac Purkinje fibers, GZ-793A at 0.03–0.3 micromolar prolonged action-potential duration. Other parameters, including resting membrane potential, action-potential amplitude and maximum depolarization rate, were not significantly altered. The published table did not provide an animal denominator for that preparation, so no rabbit sample size is inferred here.

The findings indicated potential proarrhythmic liability, not a measured incidence of arrhythmia in human patients. These cardiac effects belonged to GZ-793A testing; they were not a newly measured methamphetamine effect.

Why did favorable behavioral results not settle safety?

The early experiments addressed reinforcement, conditioned preference and selected control behaviors. They did not test the later-identified cardiac channel effects. The 2017 paper explicitly stated that GZ-793A would not be pursued as a methamphetamine-use-disorder pharmacotherapy because of those liabilities.

That was the investigators’ historical development decision. It does not establish the current status of every related compound, and no human efficacy or safety trial of GZ-793A was reported in these two papers.

The broader evidentiary lesson is that benefit, mechanism and safety require different measurements. Reduced drug seeking, lack of preference for a candidate compound and absence of weight loss cannot substitute for targeted cardiac assessment.

Scientific sources

Beckmann JS, Denehy ED, Zheng G, Crooks PA, Dwoskin LP, Bardo MT. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology. 2012;220(2):395–403. doi:10.1007/s00213-011-2488-9. Full-text author manuscript.

Nickell JR, Siripurapu KB, Horton DB, Zheng G, Crooks PA, Dwoskin LP. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. European Journal of Pharmacology. 2017;795:143–149. doi:10.1016/j.ejphar.2016.12.016. Full-text author manuscript. Historical original animal, tissue and cell studies.

The same drugs can produce different later behavior depending on what an animal does while exposed. Two experiments examining continuous d-amphetamine and cocaine reinforcement found that timing and active self-administration mattered. Their findings challenge an explanation based only on both drugs being present.

These were animal studies of operant responding. They did not establish a human treatment regimen, demonstrate clinical abstinence or justify advising someone to continue cocaine use during treatment.

What did the rhesus-monkey experiment test?

Czoty, Martelle and Nader studied four adult male rhesus monkeys with extensive cocaine self-administration and prior research-drug histories. Cocaine was available intravenously under a progressive-ratio schedule: successive injections required increasing numbers of lever presses.

After establishing baseline responding for 0.045 mg/kg cocaine per injection, investigators suspended cocaine sessions and infused d-amphetamine continuously for five days at 0.01, 0.03 or 0.1 mg/kg/hour intravenously. Each animal received all three rates in randomized order, separated by at least 14 days of baseline cocaine access.

The units are infusion rates, not single injections or daily doses. Cocaine sessions resumed on the afternoon when amphetamine infusion stopped. Food-reinforced responding was also monitored under a different schedule.

Did reduced cocaine responding persist after infusion ended?

After the 0.03 mg/kg/hour treatment, cocaine injections earned were significantly reduced for four days; after 0.1 mg/kg/hour, they were reduced for five. The lowest infusion rate did not significantly alter responding.

Food responding was also disrupted at the higher rates during treatment, and remained significantly reduced for four days after the highest rate. After the intermediate rate, post-treatment food responding remained numerically below baseline without reaching significance. The study therefore did not show an effect entirely confined to cocaine reinforcement.

Food and cocaine were available under different reinforcement schedules and were not explicitly matched for reinforcing strength. That limits claims of selective effects.

What happened when cocaine access was delayed?

In three of the monkeys, the investigators repeated the intermediate-rate treatment but inserted a planned six-day drug-free interval before restoring cocaine access. The subsequent number of cocaine injections did not differ significantly from baseline.

The contrast suggested that early experience with cocaine around the end of amphetamine treatment contributed to the longer-lasting reduction in responding. The authors proposed a learned or behavioral adaptation. They did not directly measure a neural learning mechanism or individual plasma amphetamine concentrations in this experiment.

Only one cocaine dose was used for the principal post-treatment comparison. Fewer injections at that dose cannot automatically be generalized to every dose, access condition or measure of cocaine use.

How did the rat experiment distinguish drug exposure from active responding?

Zimmer, Chiodo and Roberts studied male Sprague-Dawley rats in three groups. Eight received continuous subcutaneous d-amphetamine sulfate at 5 mg/kg/day for seven days while actively self-administering intravenous cocaine at 0.19 mg/kg per infusion. Eight received the same amphetamine treatment with passive cocaine infusions. Seven saline-pump controls actively self-administered cocaine.

The passive-infusion pattern used average timing and injection counts derived from the active amphetamine group. It approximated that group’s drug exposure rather than yoking every passive animal to one individual’s exact sequence.

The primary measure was a progressive-ratio breakpoint, operationalized as the number of cocaine infusions earned before a one-hour period passed without completing the next response requirement. Breakpoints measure behavior under an escalating work requirement, not a direct report of pleasure or a diagnosis of dependence.

What changed in the active and passive groups?

In the active amphetamine group, breakpoints fell approximately 35% from the last baseline day to the last treatment day. Group comparisons were significant on the final three treatment days. After pump removal, responding remained lower for several days before recovering.

Rats that had received passive cocaine during amphetamine treatment did not show the corresponding post-treatment reduction relative to saline controls. Thus, concurrent pharmacological exposure alone was insufficient to reproduce the observed result under this protocol.

The overall post-treatment group effect had p=.08, while the group-by-day interaction was significant and supported specific day-level comparisons. Reporting only a global “amphetamine worked” conclusion would obscure that time-dependent analysis.

Do the studies prove that learning was the sole mechanism?

No. Together, the delayed-access and passive-infusion comparisons support an associative contribution: the experience of seeking and obtaining cocaine under the changed conditions appeared important. They do not exclude pharmacological mechanisms operating alongside learning.

The studies differed in species, routes, infusion rates, treatment duration and access schedules. Their results should be compared conceptually rather than pooled into a single numerical effect. Both involved only males and relatively small groups, with no human clinical endpoint.

The practical research lesson is that exposure history includes behavior and timing, not only a list of drugs and doses. The clinical implications remained hypotheses for human testing. These experiments do not establish current treatment recommendations or the safety of amphetamine–cocaine co-use.

Scientific sources

Czoty PW, Martelle JL, Nader MA. Effects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeys. Psychopharmacology. 2010;209(4):375–382. doi:10.1007/s00213-010-1807-x. Full-text author manuscript.

Zimmer BA, Chiodo KA, Roberts DCS. Reduction of the reinforcing effectiveness of cocaine by continuous d-amphetamine treatment in rats: importance of active self-administration during treatment period. Psychopharmacology. 2014;231(5):949–954. doi:10.1007/s00213-013-3305-4. Full-text author manuscript. Both are historical original animal experiments.

Understanding why people combine drugs requires listening to their accounts without treating those accounts as proof that the combination works as intended. A multi-site qualitative study documented reasons for stimulant–opioid co-use in rural U.S. settings, including methamphetamine use intended to increase energy, offset unwanted opioid effects or respond to tolerance.

The interviews are evidence about experiences, beliefs and circumstances. They were not controlled tests of pharmacological “balance,” overdose reversal or improved functional performance.

When and where were the interviews conducted?

Fredericksen and colleagues analyzed interviews collected in 2018–2019 through the Rural Opioid Initiative. The study covered eight sites spanning ten states and 65 counties. The article was published in 2024; the accounts describe an earlier drug-market context, not a verified picture of conditions in 2026.

Participants were recruited through community programs, service providers and, at some sites, outreach. Eligibility and recruitment details varied by site. The sample was not a probability sample of all rural residents or everyone who used methamphetamine.

Researchers conducted 60–90-minute semi-structured interviews and used an iterative coding process, with independent coding and reconciliation of differences. They coded 1,672 excerpts from 349 interviews. Excerpts are units of text, not additional independent people.

What did the reported denominators mean?

Of the 349 interviewees, 137 discussed current stimulant use in the context of opioid use, reported as 39%. Within that subgroup, methamphetamine was mentioned by 78% and cocaine or crack by 26%.

The percentages concern a selected interview subgroup and are not mutually exclusive drug categories. They cannot be read as the prevalence of methamphetamine use among rural Americans, nor as a national estimate of simultaneous mixing.

The guide focused heavily on opioid use and injection. It did not systematically characterize all current non-injection stimulant use. Not discussing a behavior in this interview framework is therefore not equivalent to a standardized negative assessment of that behavior.

Which motivations emerged?

The researchers identified four broad themes. Participants described changing availability and cost; pursuit of particular combined or stronger effects; attempts to manage unwanted effects or withdrawal; and functional goals such as maintaining energy for daily work while reducing pain.

Some accounts linked adding a stimulant to reduced desired effects after repeated opioid use. These were participants’ descriptions of tolerance and their responses to it, not laboratory confirmation of an opioid tolerance mechanism or measured changes in receptor sensitivity.

Other accounts emphasized economic pressure and physically demanding work. Those narratives help explain why a person might perceive methamphetamine as useful. They do not demonstrate improved accuracy, judgment, safety or sustained productivity.

Did “concurrent” always mean simultaneous?

No. The study included accounts of simultaneous use and of using the drugs sequentially within a relatively short period. Investigators did not systematically probe exact use times, and acknowledged that their treatment of concurrent use was necessarily simplified.

The interviews therefore cannot establish a precise interval, dose, route or toxicological interaction for every account. A positive test for two drugs would require its own interpretation; it could not resolve those missing details by reference to this qualitative study.

The descriptions also should not be converted into instructions for reproducing the combinations. Their research value lies in explaining motivations and context.

Did the study show that methamphetamine reverses opioid overdose?

No. Some participants believed a stimulant could avert or reverse an opioid overdose, and the authors identified that belief as an important finding. The interviews did not include controlled overdose-reversal testing, verified dosing, continuous respiratory measurements or an adjudicated comparison of outcomes.

Current CDC guidance on polysubstance use states that stimulant and depressant effects do not simply neutralize each other and may mask effects. A person’s report of feeling more awake is therefore not proof that an opioid-related respiratory hazard has resolved.

For a suspected overdose, CDC guidance calls for an opioid-overdose reversal medication such as naloxone when available and emergency assistance. Methamphetamine should not be treated as an evidence-based substitute on the strength of these interviews. This safety context is separate from the historical study’s findings.

What are the study’s main limitations?

Self-report, selective recruitment, variable site criteria and an opioid/injection-centered interview guide limit generalization. The study did not estimate causal effects of co-use on overdose, measure blood drug concentrations or test whether perceived functional benefits were objectively present.

The authors also noted limited racial and ethnic diversity and the early timing of data collection relative to later changes in the drug supply. Descriptions of access, cost and treatment barriers are historically situated accounts rather than current market measurements.

Qualitative evidence remains useful within those limits. It can reveal reasons that a toxicology result alone cannot supply and guide better questions about exposure history, perceived benefits and barriers to care. It cannot determine an individual’s intent or validate the physiological explanation they give.

Scientific source and safety context

Fredericksen RJ, Baker R, Sibley A, et al. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry. Harm Reduction Journal. 2024;21:74. doi:10.1186/s12954-024-00986-z. Full text. Original qualitative human research using historical 2018–2019 interviews.

Safety context: CDC, Polysubstance Use Facts and Naloxone Frequently Asked Questions, checked October 29, 2026.

Reversing an amphetamine-induced laboratory change can help screen a candidate drug without establishing clinical efficacy. A rat study tested whether the experimental neurotensin receptor agonist NT69L continued to affect prepulse inhibition after 21 days of treatment. The authors reported no demonstrated loss of its effect under the studied conditions.

The tolerance question concerned NT69L’s action, not whether the rats became generally tolerant to amphetamine. This distinction is essential to reading the result.

What is prepulse inhibition?

Prepulse inhibition, or PPI, describes the reduction in a startle response when a weaker stimulus shortly precedes a stronger one. Briody and colleagues used acoustic stimuli: a 120-dB startle pulse, preceded on selected trials by a brief sound 4, 8 or 12 dB above a continuous 65-dB background.

The prepulse began 100 milliseconds before the startle pulse. PPI was calculated from the ratio of startle magnitude on paired trials to startle magnitude on pulse-only trials. It is an operational measure of sensorimotor gating, not a diagnosis of schizophrenia or a direct measure of hallucinations, judgment or driving.

Which drugs were administered?

Sprague-Dawley rats received NT69L at 1 mg/kg, haloperidol at 1 mg/kg, or the relevant control injection. Treatments were subcutaneous, either acutely or daily for 21 days. On test days, d-amphetamine at 5 mg/kg subcutaneously followed pretreatment by 30 minutes; animals entered the startle chambers 20 minutes after the amphetamine challenge.

A separate experimental series used clozapine at 20 mg/kg and a serotonin-receptor challenge drug called DOI at 0.5 mg/kg. Here “DOI” is the compound abbreviation for a substituted amphetamine, not a digital object identifier. Its results should not be merged indiscriminately with the d-amphetamine condition.

The amphetamine series evaluated whether pretreatment altered a drug-induced PPI disruption. It did not reproduce a human course of stimulant-associated psychosis or measure recovery from one.

What did the amphetamine challenge show?

D-amphetamine disrupted PPI. Acute NT69L significantly blocked that disruption at all three tested prepulse intensities. After 21 daily NT69L injections, a significant blocking effect was reported at the 12-dB prepulse intensity.

The paper found no significant difference between NT69L’s day-one and day-21 blocking effects. Its averages across prepulse intensities also supported continued activity. The authors described the findings as absence of tolerance to this antipsychotic-like effect.

That conclusion should retain its endpoint and statistical limits. The chronic result was not significant at every individual intensity, and a nonsignificant day-one versus day-21 comparison does not independently prove exact equivalence.

A separate acute dose–response experiment estimated an NT69L ED50 of 0.08 mg/kg for blocking amphetamine-disrupted PPI. This was an effect estimate within an animal assay, not a human therapeutic dose.

How large and balanced were the groups?

The study combined a separate acute experiment with day-one observations from the chronic experiment. The chronic animals were retested on day 21, but the combined day-one group was therefore not identical to the day-21 group.

For example, the pulse-alone response table lists 28 animals for NT69L plus amphetamine on day one and ten on day 21. Haloperidol-plus-amphetamine groups contained four animals at each reported time. Other controls were larger, and dose–response groups were reported as having at least eight animals.

Those unequal denominators matter. A broad range of group sizes cannot be condensed into one large sample supposedly followed identically throughout the study.

Could changes in startle amplitude explain the PPI result?

The investigators examined pulse-alone responding as well as the calculated PPI percentage. NT69L reduced startle amplitude in some conditions, including saline-treated animals, yet did not appreciably change their PPI. D-amphetamine disrupted PPI without a significant pulse-alone difference from saline controls.

The authors argued that startle amplitude and PPI effects were not simply correlated. This assessment helps interpret the ratio-based endpoint, but it does not convert PPI into a comprehensive measure of behavior or toxicity.

Repeated pretreatment also produced no significant difference in body-weight gain from saline controls. That null result concerns one measured outcome; it is not a complete safety assessment.

Why is clinical translation limited?

These were rats receiving subcutaneous drugs under tightly controlled acoustic parameters. The paper discussed differing results from another amphetamine-PPI experiment and possible contributions from testing parameters and animal source. The assay’s outcome can depend on those details.

The proposed dopamine and serotonin mechanisms were interpretations supported by related work, not a demonstration that the same mechanism treats human illness. No human symptom, retention or adverse-event trial was conducted here.

The study supports continued investigation of an experimental compound and illustrates endpoint-specific tolerance. It cannot establish that NT69L was a proven human treatment, or that preventing one amphetamine-induced response prevents all stimulant-related harms.

Scientific source

Briody S, Boules M, Oliveros A, Fauq I, Richelson E. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behavioural Brain Research. 2010;207(1):118–124; electronically published October 2, 2009. doi:10.1016/j.bbr.2009.09.044. Full-text author manuscript. Historical original rat experiment.

A drug’s later effects may depend on exposure to a different drug weeks earlier. A rat experiment found that ten days of methamphetamine pretreatment during adulthood reduced the potency of morphine in a later heat-response assay. The same pretreatment during a periadolescent period did not produce that acute morphine result.

This was a controlled animal study of antinociception, meaning suppression of a response to a noxious stimulus. It did not measure a person’s pain relief, opioid requirements, overdose risk or driving impairment.

Which exposures were compared?

Cyr and colleagues used male Sprague-Dawley rats, assigning 71 to pretreatment beginning on postnatal day 35 and 73 to pretreatment beginning on day 55. Within each age cohort, animals received saline, methamphetamine at 1 or 3 mg/kg, or methylphenidate hydrochloride at 5 mg/kg by daily intraperitoneal injection for ten consecutive days.

Two weeks after pretreatment ended, the researchers tested morphine responses: around postnatal day 60 for the earlier cohort and day 80 for the later cohort. The age cohorts were tested at different times of year, so analyses compared pretreatments with saline controls within each cohort rather than treating the study as a direct statistical comparison across ages.

The acute methamphetamine-pretreatment groups contained 16 and 19 rats at the two doses in the earlier cohort, and 17 at each dose in the adult cohort. Subsequent tolerance subgroups were smaller, generally eight or nine animals for methamphetamine conditions.

How was morphine potency measured?

Morphine sulfate was administered subcutaneously in a cumulative-dose procedure, reaching 1.8, 3.2, 5.6, 10 and 18 mg/kg at successive 20-minute intervals. Fifteen minutes after each injection, researchers measured latency to lick a hind paw on a 52.5°C hot plate, with a 50-second cutoff.

A dose–response model estimated D50, the dose associated with half-maximal antinociception under that procedure. A larger D50 indicated lower potency for this endpoint. It did not mean morphine had no effect or that its concentration was lower; drug concentrations were not measured.

Repeated readings and cumulative doses did not increase the independent animal count. The paper also acknowledged that strict blind testing procedures were not used, although the delay between pretreatment and testing reduced immediate knowledge of treatment history.

What followed adult methamphetamine pretreatment?

Both adult methamphetamine doses shifted the acute morphine dose–response curve to the right compared with saline pretreatment. The model-estimated D50 was 5.0 mg/kg after saline, 7.3 mg/kg after 1 mg/kg methamphetamine and 7.8 mg/kg after 3 mg/kg methamphetamine.

The table reported these as 5.0 ± 0.8, 7.3 ± 1.0 and 7.8 ± 1.3 mg/kg, with uncertainty described as 99% confidence intervals rather than standard deviations. The methamphetamine-group estimates fell outside the saline group’s reported 99% interval.

This was evidence of a persistent difference in the measured response two weeks after pretreatment. It did not establish the cellular mechanism or predict an individual human response.

Did the periadolescent exposure produce the same result?

No methamphetamine-pretreated group in the earlier cohort differed significantly from its saline control in acute morphine antinociception. Although the overall analysis across all pretreatments showed a difference, the paper attributed that to a comparison between methylphenidate and the lower methamphetamine dose, rather than a demonstrated methamphetamine-versus-saline effect.

Preserving the actual control comparison matters. An omnibus statistical result does not make every drug group different from control. Conversely, a nonsignificant comparison does not prove that the true effect is exactly zero.

Why were the tolerance findings less straightforward?

After the first morphine test, half of each pretreatment group received 5 mg/kg morphine subcutaneously twice daily for two days; the others received saline. The cumulative morphine test was repeated 16 hours after the final treatment.

Earlier-life pretreatment with 3 mg/kg methamphetamine was associated with greater subsequent morphine tolerance than other pretreatments. However, interpreting apparent reductions in tolerance after adult pretreatment was difficult because the groups already differed in acute morphine potency.

Even animals given saline during the two-day tolerance procedure showed a rightward shift from the first morphine test. The initial cumulative morphine exposure itself could therefore contribute to later tolerance. The saline-treated subgroup was not morphine-naive at retesting.

The paper’s percentage “shift” was calculated as the later D50 divided by the acute D50, multiplied by 100. A reported value of 204%, for example, means a later estimate about 2.04 times the original, not an additional 204% increase.

What can be inferred for human toxicology?

The experiment supports the possibility that prior stimulant exposure can alter a later response to another drug, with age and endpoint affecting the observed pattern. It does not supply an opioid dose adjustment, prove a human cross-tolerance mechanism or justify assuming that less measured antinociception means less respiratory toxicity.

All subjects were male rats; exposure was injected, and the outcome was a heat-response assay. Any clinical translation requires human evidence. The authors’ suggestion that prior stimulant history could matter clinically was a proposal for further investigation, not a validated prescribing rule.

Scientific source

Cyr MC, Ingram SL, Aicher SA, Morgan MM. Chronic psychostimulant exposure to adult, but not periadolescent rats reduces subsequent morphine antinociception. Pharmacology Biochemistry and Behavior. 2012;101(4):538–543. doi:10.1016/j.pbb.2012.02.018. Full-text author manuscript. Historical original rat experiment.

Sharing a laboratory response does not make two drugs interchangeable. A 2008 study found that repeated amphetamine or pseudoephedrine exposure reduced a later drug-induced c-Fos response in rat brain. Separate tissue experiments showed that pseudoephedrine required much higher concentrations to inhibit dopamine uptake.

The findings support overlap in selected biological responses. They do not establish equal potency, equal effects in people, or a demonstrated risk of relapse from a particular human pseudoephedrine exposure.

What did “cross-tolerance” measure?

Ruksee and colleagues studied c-Fos, a protein used as an indicator of cellular response, in the striatum and nucleus accumbens of male Sprague-Dawley rats weighing 200–250 g. The endpoint was quantified staining of a 55-kDa band on Western blots of nuclear extracts.

Cross-tolerance meant that prior repeated exposure to one drug reduced the measured response to a subsequent challenge with the other. It did not mean that the animals were shown to tolerate every behavioral, cardiovascular or toxic effect of either drug.

Results were normalized optical-density measurements, expressed relative to a control value of 100%. They were not direct measurements of pleasure, dependence, drug seeking or impairment.

How were the rats exposed?

The eight-day repeated-treatment schedules used intraperitoneal injections twice daily. Pseudoephedrine doses increased from 25 to 30 to 35 mg/kg on days one through three, then remained at 40 mg/kg on days four through eight. D-amphetamine doses increased from 1 to 2 to 2.5 mg/kg, then remained at 3 mg/kg.

According to the methods, day-nine challenges used pseudoephedrine at 40 mg/kg, amphetamine at 3 mg/kg, or saline, with tissue collected 1.5 hours later. Figure 3’s caption contains an inconsistent challenge description in its amphetamine panel, referring to pseudoephedrine there as well. The methods provide the protocol account used here; that caption inconsistency should not be silently treated as a separate confirmed regimen.

These were injected rat exposures. They cannot be equated directly with oral human doses, tablet counts or blood concentrations.

What changed after repeated treatment?

Repeated pseudoephedrine treatment reduced the acute c-Fos response to pseudoephedrine in both brain regions. Prior amphetamine or pseudoephedrine exposure also reduced responses when the other drug was used as the final challenge, which the authors interpreted as cross-tolerance.

The cross-tolerance figure reports n=3 for each brain-region analysis. Tissue from two or three similarly treated animals was pooled to obtain sufficient material for nuclear extracts. Those small assay counts therefore should not be presented as three fully independent single-rat measurements or as a large behavioral cohort.

The reduced protein response was consistent with adaptation in pathways affected by both drugs. It did not identify every molecular step responsible for that adaptation.

Did the dopamine-uptake assay show equal potency?

No. In separate synaptosomal preparations from rat brain, both drugs inhibited uptake of radiolabeled dopamine, but amphetamine was substantially more potent.

For striatal preparations, the reported half-maximal inhibitory concentrations were 4.28 ± 0.47 micromolar for amphetamine and 667 ± 126 micromolar for pseudoephedrine. In nucleus accumbens preparations, they were 2.95 ± 0.42 and 530 ± 61 micromolar, respectively. Values were reported as means ± standard errors.

The corresponding potency differences were approximately 156-fold and 180-fold. The figure reports eight striatal and four nucleus-accumbens experiments, with duplicate samples within independent experiments. Technical duplicates do not double the independent experimental count.

These concentrations describe an isolated nerve-terminal preparation under laboratory conditions. They are not therapeutic ranges, human toxic thresholds or concentrations proven to produce equivalent experiences.

Was relapse or human addiction tested?

No. The authors discussed whether pseudoephedrine could reinstate drug seeking after prior stimulant exposure and proposed additional experiments. That possibility was a research question, not a result demonstrated by the c-Fos measurements.

The study did not administer the drugs to human participants, measure human drug liking, assess oral bioavailability or follow subsequent dependence outcomes. Historical statements about availability or regulation in the paper also do not establish current legal status.

How should the evidence be used?

The paper supports a precise statement: under its repeated intraperitoneal dosing protocols, the drugs showed cross-tolerance in a selected rat brain protein response, while differing greatly in potency in a separate dopamine-uptake assay.

Keeping those endpoints separate avoids replacing a measured cellular similarity with an unsupported claim of equal human effects. Neither cross-tolerance nor chemical similarity alone establishes an individual’s impairment, clinical risk or cause of an observed event.

Scientific source

Ruksee N, Tongjaroenbuangam W, Casalotti SO, Govitrapong P. Amphetamine and pseudoephedrine cross-tolerance measured by c-Fos protein expression in brains of chronically treated rats. BMC Neuroscience. 2008;9:99. doi:10.1186/1471-2202-9-99. Full text. Historical original rat and isolated-tissue experiments.